Latest NNNN news

Top 3 Health Care Stocks That May Rocket Higher In July

Benzinga · Mon, 20 Jul 2026 06:03:18 -0400

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched Valuation

Seeking Alpha · Fri, 10 Oct 2025 12:47:30 -0400

Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers.

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

GlobeNewsWire · Fri, 08 Aug 2025 21:05:00 -0400

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.

Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

GlobeNewsWire · Thu, 15 May 2025 01:05:00 -0400

Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration

U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings

Seeking Alpha · Sat, 22 Feb 2025 00:40:00 -0500

The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahead, although some small deals may list throughout it.

Anbio Biotechnology Announces Closing of Initial Public Offering

GlobeNewsWire · Thu, 20 Feb 2025 09:50:00 -0500

Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares began trading on the Nasdaq Global Market on February 19, 2025 under the ticker symbol “NNNN.”

Anbio Biotechnology Announces Pricing of Initial Public Offering

GlobeNewsWire · Tue, 18 Feb 2025 18:10:00 -0500

Frankfurt am Main, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the pricing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (“the Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on February 19, 2025 under the ticker symbol “NNNN.”

Market information is provided for research and visualization and is not investment advice.